Movement Alert｜ImmunityBio Falls 5.17% in Regular Trading, Biotech Sector Profit-Taking Triggers Broad Pullback

Market Focus07-14 00:27

On July 14, ImmunityBio declined 5.17% in regular trading, trading at $7.805/share, with turnover of $44.70 million.

On the news front, the U.S. biotech sector experienced concentrated profit-taking after accumulating approximately 25% gains over the past month. The high-beta representative ETF (XBI) previously dropped 4% in a single session, with capital rotating structurally from high-risk small-cap biotech names toward large-cap defensive pharmaceutical companies. ImmunityBio, as a small-cap biotech stock with significant year-to-date gains, continued its pullback absent any fundamental negative catalysts.

ImmunityBio is a comprehensive immunotherapy company whose core product Anktiva has been approved in 33 countries for bladder cancer and lung cancer treatment. The company reported Q1 net product revenue of $44.2 million, representing approximately 168% year-over-year growth, with cash and marketable securities totaling $381 million as of quarter-end.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119354285?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 00:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119354285","market":"us","top_or_hot":-1,"title":"Movement Alert｜ImmunityBio Falls 5.17% in Regular Trading, Biotech Sector Profit-Taking Triggers Broad Pullback","media":"Market Focus","content":"<p><p>On July 14, ImmunityBio declined 5.17% in regular trading, trading at $7.805/share, with turnover of $44.70 million.</p><p>On the news front, the U.S. biotech sector experienced concentrated profit-taking after accumulating approximately 25% gains over the past month. The high-beta representative ETF (XBI) previously dropped 4% in a single session, with capital rotating structurally from high-risk small-cap biotech names toward large-cap defensive pharmaceutical companies. ImmunityBio, as a small-cap biotech stock with significant year-to-date gains, continued its pullback absent any fundamental negative catalysts.</p><p>ImmunityBio is a comprehensive immunotherapy company whose core product Anktiva has been approved in 33 countries for bladder cancer and lung cancer treatment. The company reported Q1 net product revenue of $44.2 million, representing approximately 168% year-over-year growth, with cash and marketable securities totaling $381 million as of quarter-end.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ImmunityBio Falls 5.17% in Regular Trading, Biotech Sector Profit-Taking Triggers Broad Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ImmunityBio Falls 5.17% in Regular Trading, Biotech Sector Profit-Taking Triggers Broad Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-14 00:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 14, ImmunityBio declined 5.17% in regular trading, trading at $7.805/share, with turnover of $44.70 million.</p><p>On the news front, the U.S. biotech sector experienced concentrated profit-taking after accumulating approximately 25% gains over the past month. The high-beta representative ETF (XBI) previously dropped 4% in a single session, with capital rotating structurally from high-risk small-cap biotech names toward large-cap defensive pharmaceutical companies. ImmunityBio, as a small-cap biotech stock with significant year-to-date gains, continued its pullback absent any fundamental negative catalysts.</p><p>ImmunityBio is a comprehensive immunotherapy company whose core product Anktiva has been approved in 33 countries for bladder cancer and lung cancer treatment. The company reported Q1 net product revenue of $44.2 million, representing approximately 168% year-over-year growth, with cash and marketable securities totaling $381 million as of quarter-end.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1119354285","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119354285","pubTimestamp":1783960076,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 14, ImmunityBio declined 5.17% in regular trading, trading at $7.805/share, with turnover of $44.70 million.On the news front, the U.S. biotech sector experienced concentrated profit-taking...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"走势警报|ImmunityBio常规交易下跌5.17%，生物技术板块获利了结引发广泛回调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"On July 14, ImmunityBio declined 5.17% in regular trading, trading at $7.805/share, with turnover of $44.70 million.On the news front, the U.S. biotech sector experienced concentrated profit-taking after accumulating approximately 25% gains over the past month. The high-beta representative ETF (XBI) previously dropped 4% in a single session, with capital rotating structurally from high-risk small-cap biotech names toward large-cap defensive pharmaceutical companies. ImmunityBio, as a small-cap biotech stock with significant year-to-date gains, continued its pullback absent any fundamental negative catalysts.ImmunityBio is a comprehensive immunotherapy company whose core product Anktiva has been approved in 33 countries for bladder cancer and lung cancer treatment. The company reported Q1 net product revenue of $44.2 million, representing approximately 168% year-over-year growth, with cash and marketable securities totaling $381 million as of quarter-end.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119354285","isCrawlerRequest":true}